In particular, as a driver role for ATR-CHK1 in supporting cancer growth has been described (Forment and O’Connor, 2018; Qiu et al., 2018; Smith et al., 2010), inhibitors of this kinase axis have been developed, primarily targeting CHK1 (Dent, 2019; Qiu et al., 2018). This evidence concerns the gene ATR and cancer.